AVOBENZONE, HOMOSALATE, OCTISALATE

AVOBENZONE, HOMOSALATE, OCTISALATE was reported 450 times

AVOBENZONE, HOMOSALATE, OCTISALATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 GASTROINTESTINAL MELANOSIS 1 0.0182
1 PINGUECULA 1 0.0094
2 EXPOSURE TO MOULD 1 0.0079
3 APPLICATION SITE NODULE 1 0.0073
4 HEAVY EXPOSURE TO ULTRAVIOLET LIGHT 1 0.0047
5 B-CELL SMALL LYMPHOCYTIC LYMPHOMA 1 0.0043
6 XEROSIS 5 0.0040
7 LENTIGO 2 0.0040
8 SOLAR DERMATITIS 1 0.0037
9 CHEMICAL BURNS OF EYE 1 0.0036
10 PREMATURE AGEING 1 0.0034
11 PYOGENIC GRANULOMA 1 0.0021
12 HYPEREOSINOPHILIC SYNDROME 1 0.0018
13 APPLICATION SITE DISCHARGE 2 0.0017
14 FUNGAL OESOPHAGITIS 1 0.0014
15 SEBORRHOEIC KERATOSIS 2 0.0014
16 GUTTATE PSORIASIS 1 0.0012
17 SUNBURN 9 0.0012
18 MILIARIA 2 0.0012
19 CATARRH 1 0.0011
20 INJECTION SITE DRYNESS 1 0.0011
21 C-REACTIVE PROTEIN 1 0.0011
22 FACIAL ASYMMETRY 1 0.0010
23 IMMUNE-MEDIATED HEPATITIS 2 0.0010
24 CHEMICAL BURN 1 0.0009
25 MALIGNANT MELANOMA IN SITU 1 0.0008
26 JOINT WARMTH 1 0.0008
27 SKIN DEPIGMENTATION 1 0.0007
28 MENINGITIS VIRAL 1 0.0007
29 VASCULAR INJURY 1 0.0007
30 CONJUNCTIVITIS ALLERGIC 1 0.0007
31 ACNE CYSTIC 2 0.0007
32 SEBORRHOEIC DERMATITIS 1 0.0006
33 ARTHROPOD STING 1 0.0006
34 MALIGNANT MELANOMA 8 0.0006
35 CHEILITIS 3 0.0006
36 NASAL OEDEMA 1 0.0006
37 APPLICATION SITE DISCOLOURATION 2 0.0005
38 DERMATITIS PSORIASIFORM 1 0.0005
39 PIGMENTATION DISORDER 3 0.0005
40 APPLICATION SITE EXFOLIATION 2 0.0005
41 WALKING DISABILITY 1 0.0005
42 SKIN HYPERPIGMENTATION 4 0.0005
43 APPLICATION SITE SCAB 1 0.0005
44 MELANOCYTIC NAEVUS 2 0.0005
45 METASTATIC MALIGNANT MELANOMA 1 0.0004
46 HAEMANGIOMA 1 0.0004
47 VITILIGO 1 0.0004
48 EYE OEDEMA 1 0.0004
49 SENSITIVE SKIN 3 0.0004
50 ACTINIC KERATOSIS 1 0.0004
51 NASAL DISORDER 1 0.0004
52 SKIN DISCOMFORT 1 0.0004
53 SKIN WRINKLING 1 0.0004
54 APPLICATION SITE HAEMORRHAGE 1 0.0004
55 PHOTOSENSITIVITY REACTION 6 0.0004
56 RED BLOOD CELL COUNT INCREASED 1 0.0004
57 VITREOUS HAEMORRHAGE 1 0.0004
58 CHOLECYSTITIS ACUTE 2 0.0004
59 SKIN WARM 2 0.0003
60 DERMATITIS 7 0.0003
61 TONGUE ULCERATION 1 0.0003
62 ABNORMAL LOSS OF WEIGHT 2 0.0003
63 SCLERODERMA 1 0.0003
64 INTENTIONAL UNDERDOSE 2 0.0003
65 OESOPHAGEAL ULCER 1 0.0003
66 THERAPEUTIC PRODUCT INEFFECTIVE 1 0.0003
67 BASAL CELL CARCINOMA 4 0.0003
68 MIOSIS 2 0.0002
69 TRIGGER FINGER 1 0.0002
70 SELF-INJURIOUS IDEATION 1 0.0002
71 OCULAR ICTERUS 1 0.0002
72 APPLICATION SITE ERYTHEMA 6 0.0002
73 SKIN TIGHTNESS 1 0.0002
74 SQUAMOUS CELL CARCINOMA 2 0.0002
75 ENDOMETRIOSIS 1 0.0002
76 INCORRECT DOSAGE ADMINISTERED 1 0.0002
77 ORGANISING PNEUMONIA 1 0.0002
78 APPLICATION SITE SWELLING 1 0.0002
79 AMMONIA INCREASED 1 0.0002
80 ANAL FISTULA 1 0.0002
81 APPLICATION SITE PAIN 4 0.0002
82 HYPERKERATOSIS 1 0.0002
83 ANGIOPATHY 1 0.0002
84 ACUTE PULMONARY OEDEMA 1 0.0002
85 GENERALISED ERYTHEMA 1 0.0002
86 SKIN ATROPHY 1 0.0002
87 RALES 1 0.0002
88 HYPERTRIGLYCERIDAEMIA 1 0.0002
89 CATARACT OPERATION 1 0.0002
90 PRE-EXISTING CONDITION IMPROVED 1 0.0002
91 APPLICATION SITE VESICLES 1 0.0002
92 IMMUNE SYSTEM DISORDER 2 0.0002
93 SKIN MASS 1 0.0001
94 PAIN OF SKIN 4 0.0001
95 DROOLING 1 0.0001
96 ENCEPHALITIS 1 0.0001
97 APPLICATION SITE REACTION 1 0.0001
98 RETINAL HAEMORRHAGE 1 0.0001
99 DRUG ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 1 0.0001
100 SKIN HAEMORRHAGE 2 0.0001
101 ACNE 10 0.0001
102 LOW DENSITY LIPOPROTEIN INCREASED 1 0.0001
103 PULMONARY HAEMORRHAGE 1 0.0001
104 PRODUCT ADMINISTRATION INTERRUPTED 1 0.0001
105 MUSCLE DISORDER 1 0.0001
106 HYPERAESTHESIA 1 0.0001
107 SKIN PLAQUE 1 0.0001
108 CARDIAC MURMUR 1 0.0001
109 NAIL DISORDER 1 0.0001
110 BLOOD CALCIUM INCREASED 1 0.0001
111 IMMUNOSUPPRESSION 1 0.0001
112 LIP DRY 1 0.0001
113 MOOD ALTERED 3 0.0001
114 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 2 0.0001
115 SPINAL DISORDER 1 0.0001
116 CHOLESTASIS 2 0.0001
117 PETECHIAE 1 0.0001
118 POOR QUALITY PRODUCT ADMINISTERED 1 0.0001
119 SCRATCH 1 0.0001
120 SWELLING FACE 6 0.0001
121 ASPIRATION 1 0.0001
122 NERVE INJURY 1 0.0001
123 RASH PAPULAR 2 0.0001
124 THERAPEUTIC RESPONSE UNEXPECTED 4 0.0001
125 BLISTER 5 0.0001
126 DERMATITIS CONTACT 1 0.0001
127 SCAB 1 0.0001
128 VASCULITIS 1 0.0001
129 SYSTEMIC LUPUS ERYTHEMATOSUS 3 0.0001
130 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 6 0.0001
131 RASH ERYTHEMATOUS 4 0.0001
132 CARDIOMEGALY 1 0.0001
133 APPLICATION SITE IRRITATION 1 0.0001
134 HAIR COLOUR CHANGES 1 0.0001
135 DRY EYE 4 0.0001
136 NODULE 1 0.0001
137 ECZEMA 4 0.0001
138 INCORRECT PRODUCT STORAGE 1 0.0001
139 TACHYPNOEA 1 0.0001
140 SKIN LESION 2 0.0001
141 APPLICATION SITE RASH 1 0.0001
142 SKIN REACTION 1 0.0001
143 BRONCHOSPASM 1 0.0001
144 SKIN BURNING SENSATION 5 0.0001
145 DRUG EFFECT LESS THAN EXPECTED 1 0.0001
146 DRY SKIN 9 0.0001
147 SKIN IRRITATION 3 0.0001
148 SKIN DISCOLOURATION 3 0.0001
149 BACK DISORDER 1 0.0001
150 SKIN EXFOLIATION 5 0.0001
151 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 1 0.0001
152 SCAR 1 0.0001
153 MUSCULOSKELETAL DISCOMFORT 1 0.0001
154 RASH MACULAR 2 0.0001
155 BURNING SENSATION 4 0.0001
156 THIRST 1 0.0001
157 GASTROENTERITIS VIRAL 1 0.0001
158 OSTEOMYELITIS 1 0.0001
159 BACTERIAL INFECTION 1 0.0001
160 GASTRIC ULCER 1 0.0001
161 DISABILITY 1 0.0001
162 PSORIATIC ARTHROPATHY 2 0.0000
163 INJURY ASSOCIATED WITH DEVICE 1 0.0000
164 LUNG NEOPLASM MALIGNANT 2 0.0000
165 ERYTHEMA 10 0.0000
166 MOUTH ULCERATION 1 0.0000
167 LIVER FUNCTION TEST INCREASED 1 0.0000
168 SKIN CANCER 1 0.0000
169 INCORRECT PRODUCT ADMINISTRATION DURATION 1 0.0000
170 RASH MACULO-PAPULAR 1 0.0000
171 GLOSSODYNIA 1 0.0000
172 SNEEZING 1 0.0000
173 APPLICATION SITE PRURITUS 1 0.0000
174 PRODUCT AVAILABILITY ISSUE 1 0.0000
175 UNDERDOSE 3 0.0000
176 HYPOPHAGIA 1 0.0000
177 HEPATITIS 1 0.0000
178 INFLAMMATION 2 0.0000
179 PSORIASIS 5 0.0000
180 JOINT STIFFNESS 1 0.0000
181 JAUNDICE 1 0.0000
182 FREQUENT BOWEL MOVEMENTS 1 0.0000
183 RASH 16 0.0000
184 WOUND 1 0.0000
185 INCORRECT DRUG ADMINISTRATION DURATION 1 0.0000
186 EYE PAIN 2 0.0000
187 INTENTIONAL DOSE OMISSION 1 0.0000
188 HYPERSOMNIA 1 0.0000
189 EYE IRRITATION 2 0.0000
190 BLOOD CREATINE PHOSPHOKINASE INCREASED 1 0.0000
191 INTENTIONAL PRODUCT MISUSE 3 0.0000
192 MUSCULOSKELETAL STIFFNESS 3 0.0000
193 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 1 0.0000
194 ASCITES 1 0.0000
195 PSYCHOTIC DISORDER 1 0.0000
196 URINARY INCONTINENCE 1 0.0000
197 RESPIRATORY DISORDER 1 0.0000
198 CONTRAINDICATED PRODUCT ADMINISTERED 1 0.0000
199 DISCOMFORT 2 0.0000
200 SWELLING 3 0.0000
201 HEART RATE INCREASED 3 0.0000
202 EXPIRED PRODUCT ADMINISTERED 1 0.0000
203 SKIN DISORDER 1 0.0000
204 URINARY RETENTION 1 0.0000
205 TYPE 2 DIABETES MELLITUS 1 0.0000
206 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 1 0.0000
207 HAEMATURIA 1 0.0000
208 ILLNESS 3 0.0000
209 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 2 0.0000
210 MYELOSUPPRESSION 1 0.0000
211 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 5 0.0000
212 DRUG EFFECT INCOMPLETE 1 0.0000
213 HYPERGLYCAEMIA 1 0.0000
214 INJECTION SITE MASS 1 0.0000
215 PRODUCT USE ISSUE 5 0.0000
216 DYSPNOEA EXERTIONAL 1 0.0000
217 PLASMA CELL MYELOMA 1 0.0000
218 DRY MOUTH 2 0.0000
219 GASTROINTESTINAL HAEMORRHAGE 2 0.0000
220 RECTAL HAEMORRHAGE 1 0.0000
221 INTENTIONAL PRODUCT USE ISSUE 2 0.0000
222 TACHYCARDIA 2 0.0000
223 DEPRESSION 5 0.0000
224 NEPHROLITHIASIS 1 0.0000
225 ADVERSE EVENT 2 0.0000
226 UPPER RESPIRATORY TRACT INFECTION 1 0.0000
227 HYPERSENSITIVITY 4 0.0000
228 BLOOD CHOLESTEROL INCREASED 1 0.0000
229 OCULAR HYPERAEMIA 1 0.0000
230 DYSPHAGIA 2 0.0000
231 DISEASE RECURRENCE 1 0.0000
232 PRODUCTIVE COUGH 1 0.0000
233 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 1 0.0000
234 CONTUSION 2 0.0000
235 DRUG INTOLERANCE 2 0.0000
236 SOMNOLENCE 4 0.0000
237 CONDITION AGGRAVATED 6 0.0000
238 HOSPITALISATION 3 0.0000
239 ASPARTATE AMINOTRANSFERASE INCREASED 1 0.0000
240 RASH PRURITIC 1 0.0000
241 OEDEMA 1 0.0000
242 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 1 0.0000
243 URTICARIA 3 0.0000
244 OXYGEN SATURATION DECREASED 1 0.0000
245 FLATULENCE 1 0.0000
246 CONVULSION 1 0.0000
247 SEIZURE 2 0.0000
248 NASAL CONGESTION 1 0.0000
249 JOINT SWELLING 2 0.0000
250 STOMATITIS 1 0.0000
251 FEELING HOT 1 0.0000
252 ALANINE AMINOTRANSFERASE INCREASED 1 0.0000
253 PRURITUS 6 0.0000
254 HYPERHIDROSIS 2 0.0000
255 PRODUCT DOSE OMISSION 1 0.0000
256 BLOOD PRESSURE DECREASED 1 0.0000
257 INJECTION SITE PRURITUS 1 0.0000
258 PRODUCT QUALITY ISSUE 2 0.0000
259 INJECTION SITE REACTION 1 0.0000
260 SLEEP DISORDER 1 0.0000
261 MOBILITY DECREASED 1 0.0000
262 OVERDOSE 3 0.0000
263 INFECTION 2 0.0000
264 RESPIRATORY FAILURE 1 0.0000
265 EPISTAXIS 1 0.0000
266 HOT FLUSH 1 0.0000
267 DIABETES MELLITUS 1 0.0000
268 INJECTION SITE SWELLING 1 0.0000
269 PERIPHERAL SWELLING 2 0.0000
270 INJECTION SITE HAEMORRHAGE 1 0.0000
271 INFLUENZA LIKE ILLNESS 1 0.0000
272 ARTHRALGIA 5 0.0000
273 ABDOMINAL DISCOMFORT 2 0.0000
274 MYALGIA 2 0.0000
275 BALANCE DISORDER 1 0.0000
276 PRODUCT STORAGE ERROR 1 0.0000
277 HEADACHE 7 0.0000
278 GASTROINTESTINAL DISORDER 1 0.0000
279 SUICIDAL IDEATION 1 0.0000
280 MUSCLE SPASMS 2 0.0000
281 DIARRHOEA 7 0.0000
282 WEIGHT DECREASED 3 0.0000
283 COUGH 3 0.0000
284 ANXIETY 3 0.0000
285 PULMONARY EMBOLISM 1 0.0000
286 MIGRAINE 1 0.0000
287 ATRIAL FIBRILLATION 1 0.0000
288 PRODUCT DOSE OMISSION ISSUE 3 0.0000
289 PAIN IN EXTREMITY 3 0.0000
290 DYSPEPSIA 1 0.0000
291 FLUSHING 1 0.0000
292 PAIN 6 0.0000
293 ABDOMINAL PAIN UPPER 2 0.0000
294 ACCIDENTAL EXPOSURE TO PRODUCT 1 0.0000
295 ABDOMINAL DISTENSION 1 0.0000
296 HAEMORRHAGE 1 0.0000
297 MALAISE 4 0.0000
298 INFLUENZA 1 0.0000
299 SEPSIS 1 0.0000
300 ASTHMA 1 0.0000
301 MUSCULAR WEAKNESS 1 0.0000
302 GENERAL PHYSICAL HEALTH DETERIORATION 1 0.0000
303 DECREASED APPETITE 2 0.0000
304 BACK PAIN 2 0.0000
305 PALPITATIONS 1 0.0000
306 DISEASE PROGRESSION 1 0.0000
307 OFF LABEL USE 7 0.0000
308 ASTHENIA 3 0.0000
309 FATIGUE 6 0.0000
310 DEHYDRATION 1 0.0000
311 NEUTROPENIA 1 0.0000
312 VISION BLURRED 1 0.0000
313 BLOOD PRESSURE INCREASED 1 0.0000
314 ACUTE KIDNEY INJURY 1 0.0000
315 CONFUSIONAL STATE 1 0.0000
316 PNEUMONIA 2 0.0000
317 FALL 2 0.0000
318 CEREBROVASCULAR ACCIDENT 1 0.0000
319 PYREXIA 2 0.0000
320 COVID-19 1 0.0000
321 NASOPHARYNGITIS 1 0.0000
322 CHEST PAIN 1 0.0000
323 BLOOD GLUCOSE INCREASED 1 0.0000
324 ANAEMIA 1 0.0000
325 GAIT DISTURBANCE 1 0.0000
326 ALOPECIA 1 0.0000
327 HYPOTENSION 1 0.0000
328 HYPERTENSION 1 0.0000
329 CONSTIPATION 1 0.0000
330 WEIGHT INCREASED 1 0.0000
331 ABDOMINAL PAIN 1 0.0000
332 PRODUCT USE IN UNAPPROVED INDICATION 1 0.0000
333 DRUG INEFFECTIVE 5 0.0000
334 NAUSEA 3 0.0000
335 INSOMNIA 1 0.0000
336 DYSPNOEA 2 0.0000
337 INJECTION SITE PAIN 1 0.0000
338 DEATH 2 0.0000
339 VOMITING 1 0.0000